Last reviewed · How we verify

Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin

Global Alliance for TB Drug Development · Phase 3 active Small molecule

Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin is a Anti-tuberculosis agent combination Small molecule drug developed by Global Alliance for TB Drug Development. It is currently in Phase 3 development for Tuberculosis (drug-susceptible and multidrug-resistant forms). Also known as: Avelox, Avelon, Avalox, Myambutol.

This is a fixed-dose combination of five anti-tuberculosis agents that work through multiple mechanisms to inhibit bacterial cell wall synthesis, protein synthesis, and DNA replication in Mycobacterium tuberculosis.

This is a fixed-dose combination of five anti-tuberculosis agents that work through multiple mechanisms to inhibit bacterial cell wall synthesis, protein synthesis, and DNA replication in Mycobacterium tuberculosis. Used for Tuberculosis (drug-susceptible and multidrug-resistant forms).

At a glance

Generic nameMoxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin
Also known asAvelox, Avelon, Avalox, Myambutol, Nydrazid
SponsorGlobal Alliance for TB Drug Development
Drug classAnti-tuberculosis agent combination
TargetMultiple: DNA gyrase (moxifloxacin), RNA polymerase (rifampicin), mycolic acid synthesis (isoniazid, pyrazinamide), arabinosyl transferase (ethambutol)
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

Moxifloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase; Rifampicin inhibits bacterial RNA polymerase; Isoniazid and Pyrazinamide inhibit mycobacterial cell wall synthesis and metabolism; Ethambutol inhibits arabinosyl transferases involved in cell wall synthesis. The combination provides synergistic activity against drug-susceptible and multidrug-resistant tuberculosis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin

What is Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin?

Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin is a Anti-tuberculosis agent combination drug developed by Global Alliance for TB Drug Development, indicated for Tuberculosis (drug-susceptible and multidrug-resistant forms).

How does Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin work?

This is a fixed-dose combination of five anti-tuberculosis agents that work through multiple mechanisms to inhibit bacterial cell wall synthesis, protein synthesis, and DNA replication in Mycobacterium tuberculosis.

What is Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin used for?

Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin is indicated for Tuberculosis (drug-susceptible and multidrug-resistant forms).

Who makes Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin?

Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin is developed by Global Alliance for TB Drug Development (see full Global Alliance for TB Drug Development pipeline at /company/global-alliance-for-tb-drug-development).

Is Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin also known as anything else?

Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin is also known as Avelox, Avelon, Avalox, Myambutol, Nydrazid.

What drug class is Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin in?

Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin belongs to the Anti-tuberculosis agent combination class. See all Anti-tuberculosis agent combination drugs at /class/anti-tuberculosis-agent-combination.

What development phase is Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin in?

Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin is in Phase 3.

What are the side effects of Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin?

Common side effects of Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin include Gastrointestinal disturbances (nausea, vomiting, diarrhea), Hepatotoxicity, Peripheral neuropathy, Hyperuricemia, Optic neuritis (ethambutol-related), Photosensitivity (moxifloxacin-related).

What does Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin target?

Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin targets Multiple: DNA gyrase (moxifloxacin), RNA polymerase (rifampicin), mycolic acid synthesis (isoniazid, pyrazinamide), arabinosyl transferase (ethambutol) and is a Anti-tuberculosis agent combination.

Related